Gail Farfel

Gail M.
Farfel currently works at Dravet Syndrome Foundation, Inc., as Director, PrintedArt, as Director, FAAH Pharma, Inc., as Director from 2014, and American Society For Experimental Neurotherapeutics, as Director.
Dr. Farfel also formerly worked at ProMIS Neurosciences, Inc., as President, Chief Executive Officer & Director in 2023, Pfizer Inc., as Senior Associate Director, DURECT Corp., as Independent Director from 2019 to 2025, Zogenix International Ltd., as Director from 2015 to 2022, AVROBIO, Inc., as Director from 2020 to 2024, Marinus Pharmaceuticals, Inc., as Chief Clinical & Regulatory Officer from 2012 to 2015, Novartis Pharmaceuticals Corp., as VP-Therapeutic Area & Head-Neuroscience from 2006 to 2008, Pfizer Pharmaceuticals, Inc., as Global Team Lead from 1994 to 2006, G Meredith Consulting LLC, as President in 2012, and Zogenix, Inc., as Chief Development Officer & Executive VP from 2015 to 2022.
Dr. Farfel received her undergraduate degree from the University of Virginia and doctorate degree from The University of Chicago.